Grifols SA
ISIN US3984384087
|WKN A1J1E2
Overview
Description
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.
Healthcare Biopharmaceuticals Other Biopharmaceuticals Spain
Financials
Key metrics
| Market capitalisation, EUR | 5,763.28 m |
| EPS, EUR | 0.23 |
| P/B ratio | 0.82 |
| P/E ratio | 82.42 |
| Dividend yield | 0.00% |
Income statement (2023)
| Revenue, EUR | 6,592.07 m |
| Net income, EUR | 59.32 m |
| Profit margin | 0.90% |
What ETF is Grifols SA in?
There are 7 ETFs which contain Grifols SA. All of these ETFs are listed in the table below. The ETF with the largest weighting of Grifols SA is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
| ETF | Weight | Investment focus | Holdings | TER | Fund size (in m EUR) | Return 1Y | WKN | ISIN |
|---|---|---|---|---|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 0.09% | Equity United States Health Care Biotech | 216 | 0.35% | 37 | +22.93% | A2JDYM | IE00BDZVHG35 |
| Amundi S&P Global Health Care ESG UCITS ETF DR EUR (A) | 0.02% | Equity World Health Care Social/Environmental | 110 | 0.18% | 224 | +18.48% | A3DSTC | IE0006FM6MI8 |
| iShares Nasdaq US Biotechnology UCITS ETF | 0.09% | Equity United States Health Care Biotech | 216 | 0.35% | 498 | +22.66% | A2DWAW | IE00BYXG2H39 |
| Amundi S&P Eurozone PAB Net Zero Ambition UCITS ETF Acc | 0.03% | Equity Europe Social/Environmental Climate Change | 130 | 0.20% | 1,822 | +15.04% | LYX05H | LU2195226068 |
| Amundi S&P Global Health Care ESG UCITS ETF DR EUR (D) | 0.02% | Equity World Health Care Social/Environmental | 110 | 0.18% | 20 | +18.50% | A3DSTD | IE000JKS50V3 |
| Xtrackers S&P Europe ex UK UCITS ETF | 0.02% | Equity Europe | 343 | 0.09% | 611 | +14.43% | A2JCAG | IE00BGV5VM45 |
| Invesco S&P World Health Care ESG UCITS ETF Acc | 0.03% | Equity World Health Care Social/Environmental | 89 | 0.18% | 2 | +19.30% | A3D3BE | IE000L4EH2K5 |
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.